Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes
Conditions
Keywords
Myelodysplastic Syndromes, MDS, Chronic Myelomonocytic Leukemia, CMML, Acute Myeloid Leukemia, AML, Vidaza, oral azacitidine, aza, oral aza, pharmacokinetics, hematology, myeloid disease, PK
Brief summary
The primary purpose of this study is to evaluate the pharmacokinetics of oral azacitidine when administered once daily as two 150-mg tablets, including the effect of food, and to evaluate the bioavailability of oral azacitidine 300-mg when administered as two 150-mg tablets relative to three 100-mg tablets.
Interventions
DRUGoral azacitidine
oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
Sponsors
Celgene
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older at the time of signing the informed consent document * Diagnosis of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * At least 3 month life expectancy * Adequate organ function, defined as: * Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN); * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the ULN; * Serum creatinine ≤ 1.5 times the ULN; * Serum bicarbonate ≥ 20 mEq/L * Females of childbearing potential (FCBP) must: * Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study, and for 3 months following the last dose of oral azacitidine; and * Have a negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) at screening; and * Have a negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) within 72 hours prior to Day 1 of the pharmacokinetic (PK) phase (note that the screening pregnancy test can be used as the test prior to Day 1 of the PK phase if it is performed within the 72 hour timeframe). * Males with partners who are FCBP must agree that they and their partners will use at least two effective contraceptive methods throughout the study and will avoid fathering a child for 3 months following the date of last oral azacitidine dosing * Understand and voluntarily sign an informed consent document prior to the start of any study related assessments/procedures * Able to adhere to the study visit schedule and other protocol requirements
Exclusion criteria
* Suspected or proven acute promyelocytic leukemia based on morphology, immunophenotype, molecular assay, or karyotype * Previous treatment with azacitidine or other demethylating agents within 21 days prior to starting study therapy or ongoing adverse events from previous treatment, regardless of the time period * Anticancer therapy (standard or investigational) within 21 days prior to starting study therapy or ongoing adverse events from previous treatment, regardless of the time period * Use of any proton pump inhibitor or any other agent that may affect gastric acid level within 28 days prior to study therapy (only applicable to Part II of the PK phase) * Concurrent use of erythropoiesis-stimulating agents (ESAs) and other red blood cell hematopoietic growth factors, except that the subject is on a stable dose for at least 4 weeks (28 days) prior to starting study therapy * Concurrent use of iron-chelating agents, except that the subject is on a stable dose for at least 8 weeks (56 days) prior to starting study therapy * Concurrent corticosteroid use, except for medical conditions other than Myelodysplastic Syndrome and provided the subject is on a stable or decreasing dose for ≥ 1 week prior to start study therapy * Pregnant or lactating females * Any known or suspected hypersensitivity to azacitidine or mannitol or any other ingredient used in the manufacture of oral azacitidine (see the azacitidine IB) * Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment) * Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C * Presence of gastrointestinal disease, malignant hepatic tumors, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs * Current congestive heart failure (New York Heart Association Class III-IV Appendix G), unstable angina or angina requiring surgical or medical intervention within 6 months prior to starting study therapy, myocardial infarct within 6 months prior to starting study therapy, or uncontrolled cardiac arrhythmia (defined as arrhythmia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia). Subjects with controlled atrial fibrillation that is asymptomatic are eligible * Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study * Any condition that confounds the ability to interpret data from the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK-(Tmax) | Up to 10 days | PK-Time to maximum plasma concentration (Tmax) |
| To evaluate the effect of gastric acid pH modulation, through a proton pump inhibitor, on the PK of oral azacitidine | Up to 10 days | To evaluate the effect of gastric acid pH modulation, through a proton pump inhibitor, on the PK of oral azacitidine. |
| PK-(AUC) | Up to 10 days | PK-Area under the plasma concentration time curve (AUC) |
| PK-(T½) | Up to 10 days | PK-Terminal half-life (T½) |
| PK-(Cmax) | Up to 10 days | Observed maximum concentration in plasma (Cmax) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hematological response/improvement | Up to 2 years | Proportion of subjects achieving hematological response/improvement |
| Transfusion independence | Up to 2 years | Proportion of subjects achieving RBC transfusion independence |
| Platelet transfusion independence | Up to 2 years | Proportion of subjects achieving platelet transfusion independence |
| Adverse Events | Up to 2 years | Number of participants with adverse events |
Countries
United States
Outcome results
None listed